nodes	percent_of_prediction	percent_of_DWPC	metapath
Prazosin—SLC22A3—Melphalan—ovarian cancer	0.287	0.478	CbGbCtD
Prazosin—ABCB1—ovarian cancer	0.218	1	CbGaD
Prazosin—ABCG2—Topotecan—ovarian cancer	0.0869	0.145	CbGbCtD
Prazosin—ABCG2—Paclitaxel—ovarian cancer	0.043	0.0717	CbGbCtD
Prazosin—ABCG2—Carboplatin—ovarian cancer	0.0405	0.0675	CbGbCtD
Prazosin—ABCB1—Topotecan—ovarian cancer	0.0313	0.0522	CbGbCtD
Prazosin—ABCG2—Docetaxel—ovarian cancer	0.0311	0.0518	CbGbCtD
Prazosin—ABCG2—Doxorubicin—ovarian cancer	0.0232	0.0386	CbGbCtD
Prazosin—ABCB1—Vinorelbine—ovarian cancer	0.0221	0.0368	CbGbCtD
Prazosin—ABCB1—Paclitaxel—ovarian cancer	0.0155	0.0258	CbGbCtD
Prazosin—ABCB1—Docetaxel—ovarian cancer	0.0112	0.0187	CbGbCtD
Prazosin—ABCB1—Doxorubicin—ovarian cancer	0.00836	0.0139	CbGbCtD
Prazosin—MT3—testis—ovarian cancer	0.00212	0.0419	CbGeAlD
Prazosin—KCNH7—testis—ovarian cancer	0.00212	0.0419	CbGeAlD
Prazosin—KCNH6—uterus—ovarian cancer	0.00208	0.0412	CbGeAlD
Prazosin—KCNH6—female reproductive system—ovarian cancer	0.00187	0.037	CbGeAlD
Prazosin—MT3—lymph node—ovarian cancer	0.00153	0.0304	CbGeAlD
Prazosin—ADRA1D—epithelium—ovarian cancer	0.00139	0.0276	CbGeAlD
Prazosin—SLC22A3—myometrium—ovarian cancer	0.00128	0.0254	CbGeAlD
Prazosin—SLC22A3—embryo—ovarian cancer	0.00123	0.0244	CbGeAlD
Prazosin—ADRA1D—female reproductive system—ovarian cancer	0.00104	0.0205	CbGeAlD
Prazosin—ORM1—endometrium—ovarian cancer	0.00103	0.0204	CbGeAlD
Prazosin—SLC22A3—uterine cervix—ovarian cancer	0.000996	0.0197	CbGeAlD
Prazosin—KCNH2—myometrium—ovarian cancer	0.000985	0.0195	CbGeAlD
Prazosin—SLC22A3—endometrium—ovarian cancer	0.000901	0.0179	CbGeAlD
Prazosin—ABCG2—myometrium—ovarian cancer	0.000876	0.0174	CbGeAlD
Prazosin—ORM1—female reproductive system—ovarian cancer	0.000853	0.0169	CbGeAlD
Prazosin—Terazosin—ABCB1—ovarian cancer	0.000841	0.574	CrCbGaD
Prazosin—SLC22A3—gonad—ovarian cancer	0.000836	0.0166	CbGeAlD
Prazosin—ORM1—bone marrow—ovarian cancer	0.000805	0.016	CbGeAlD
Prazosin—ADRA1A—epithelium—ovarian cancer	0.000801	0.0159	CbGeAlD
Prazosin—ADRA2A—myometrium—ovarian cancer	0.000776	0.0154	CbGeAlD
Prazosin—HTR1D—female reproductive system—ovarian cancer	0.000774	0.0153	CbGeAlD
Prazosin—KCNH2—uterine cervix—ovarian cancer	0.000767	0.0152	CbGeAlD
Prazosin—SLC22A3—female reproductive system—ovarian cancer	0.000747	0.0148	CbGeAlD
Prazosin—SLC22A1—vagina—ovarian cancer	0.000706	0.014	CbGeAlD
Prazosin—KCNH2—endometrium—ovarian cancer	0.000693	0.0137	CbGeAlD
Prazosin—ABCG2—uterine cervix—ovarian cancer	0.000682	0.0135	CbGeAlD
Prazosin—SLC22A3—female gonad—ovarian cancer	0.000679	0.0135	CbGeAlD
Prazosin—SLC22A3—vagina—ovarian cancer	0.000675	0.0134	CbGeAlD
Prazosin—CYP1A1—epithelium—ovarian cancer	0.000653	0.0129	CbGeAlD
Prazosin—ABCG2—decidua—ovarian cancer	0.00065	0.0129	CbGeAlD
Prazosin—CYP1A1—uterine cervix—ovarian cancer	0.000647	0.0128	CbGeAlD
Prazosin—KCNH2—uterus—ovarian cancer	0.000639	0.0127	CbGeAlD
Prazosin—Doxazosin—ABCB1—ovarian cancer	0.000626	0.427	CrCbGaD
Prazosin—ABCG2—endometrium—ovarian cancer	0.000617	0.0122	CbGeAlD
Prazosin—ADRA2A—uterine cervix—ovarian cancer	0.000604	0.012	CbGeAlD
Prazosin—SLC22A3—testis—ovarian cancer	0.000602	0.0119	CbGeAlD
Prazosin—ADRA2A—decidua—ovarian cancer	0.000575	0.0114	CbGeAlD
Prazosin—KCNH2—female reproductive system—ovarian cancer	0.000574	0.0114	CbGeAlD
Prazosin—ABCG2—uterus—ovarian cancer	0.000568	0.0113	CbGeAlD
Prazosin—ADRA2A—endometrium—ovarian cancer	0.000546	0.0108	CbGeAlD
Prazosin—KCNH2—bone marrow—ovarian cancer	0.000542	0.0107	CbGeAlD
Prazosin—CYP1A1—uterus—ovarian cancer	0.00054	0.0107	CbGeAlD
Prazosin—KCNH2—female gonad—ovarian cancer	0.000523	0.0104	CbGeAlD
Prazosin—KCNH2—vagina—ovarian cancer	0.000519	0.0103	CbGeAlD
Prazosin—ADRA2A—gonad—ovarian cancer	0.000506	0.01	CbGeAlD
Prazosin—ADRA2A—uterus—ovarian cancer	0.000503	0.00997	CbGeAlD
Prazosin—ORM1—lymph node—ovarian cancer	0.000499	0.00988	CbGeAlD
Prazosin—Alopecia—Vinorelbine—ovarian cancer	0.000498	0.00617	CcSEcCtD
Prazosin—Arthralgia—Topotecan—ovarian cancer	0.000488	0.00605	CcSEcCtD
Prazosin—CYP1A1—female reproductive system—ovarian cancer	0.000485	0.00961	CbGeAlD
Prazosin—Discomfort—Topotecan—ovarian cancer	0.000482	0.00598	CcSEcCtD
Prazosin—ABCG2—bone marrow—ovarian cancer	0.000482	0.00956	CbGeAlD
Prazosin—ABCG2—female gonad—ovarian cancer	0.000465	0.00921	CbGeAlD
Prazosin—Pancreatitis—Paclitaxel—ovarian cancer	0.000464	0.00575	CcSEcCtD
Prazosin—KCNH2—testis—ovarian cancer	0.000464	0.00919	CbGeAlD
Prazosin—ABCG2—vagina—ovarian cancer	0.000462	0.00916	CbGeAlD
Prazosin—Sweating increased—Paclitaxel—ovarian cancer	0.000461	0.00572	CcSEcCtD
Prazosin—Oedema—Melphalan—ovarian cancer	0.000458	0.00568	CcSEcCtD
Prazosin—Ill-defined disorder—Vinorelbine—ovarian cancer	0.000455	0.00564	CcSEcCtD
Prazosin—Fatigue—Chlorambucil—ovarian cancer	0.000453	0.00562	CcSEcCtD
Prazosin—Hyperhidrosis—Topotecan—ovarian cancer	0.000452	0.00561	CcSEcCtD
Prazosin—ADRA2A—female reproductive system—ovarian cancer	0.000452	0.00896	CbGeAlD
Prazosin—Pain—Chlorambucil—ovarian cancer	0.00045	0.00557	CcSEcCtD
Prazosin—Tachycardia—Melphalan—ovarian cancer	0.000447	0.00554	CcSEcCtD
Prazosin—Malaise—Vinorelbine—ovarian cancer	0.000442	0.00548	CcSEcCtD
Prazosin—CYP1A1—female gonad—ovarian cancer	0.000441	0.00875	CbGeAlD
Prazosin—Vertigo—Vinorelbine—ovarian cancer	0.000441	0.00546	CcSEcCtD
Prazosin—CYP1A1—vagina—ovarian cancer	0.000439	0.00869	CbGeAlD
Prazosin—Pollakiuria—Paclitaxel—ovarian cancer	0.000437	0.00542	CcSEcCtD
Prazosin—SLC22A3—lymph node—ovarian cancer	0.000437	0.00865	CbGeAlD
Prazosin—Palpitations—Vinorelbine—ovarian cancer	0.000434	0.00537	CcSEcCtD
Prazosin—Feeling abnormal—Chlorambucil—ovarian cancer	0.000433	0.00537	CcSEcCtD
Prazosin—ABCB1—myometrium—ovarian cancer	0.000432	0.00856	CbGeAlD
Prazosin—Musculoskeletal discomfort—Topotecan—ovarian cancer	0.000426	0.00528	CcSEcCtD
Prazosin—Orthostatic hypotension—Docetaxel—ovarian cancer	0.000424	0.00526	CcSEcCtD
Prazosin—Paraesthesia—Topotecan—ovarian cancer	0.00042	0.00521	CcSEcCtD
Prazosin—Urticaria—Chlorambucil—ovarian cancer	0.000418	0.00518	CcSEcCtD
Prazosin—Arthralgia—Vinorelbine—ovarian cancer	0.000418	0.00518	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Melphalan—ovarian cancer	0.000418	0.00517	CcSEcCtD
Prazosin—Dyspnoea—Topotecan—ovarian cancer	0.000417	0.00517	CcSEcCtD
Prazosin—ABCB1—embryo—ovarian cancer	0.000416	0.00824	CbGeAlD
Prazosin—Body temperature increased—Chlorambucil—ovarian cancer	0.000416	0.00515	CcSEcCtD
Prazosin—Discomfort—Vinorelbine—ovarian cancer	0.000413	0.00511	CcSEcCtD
Prazosin—ABCG2—testis—ovarian cancer	0.000412	0.00817	CbGeAlD
Prazosin—Paraesthesia—Melphalan—ovarian cancer	0.000412	0.0051	CcSEcCtD
Prazosin—ADRA2A—female gonad—ovarian cancer	0.000411	0.00815	CbGeAlD
Prazosin—ADRA2A—vagina—ovarian cancer	0.000409	0.0081	CbGeAlD
Prazosin—Dyspnoea—Melphalan—ovarian cancer	0.000409	0.00506	CcSEcCtD
Prazosin—Fatigue—Topotecan—ovarian cancer	0.000404	0.005	CcSEcCtD
Prazosin—Pain—Topotecan—ovarian cancer	0.0004	0.00496	CcSEcCtD
Prazosin—Constipation—Topotecan—ovarian cancer	0.0004	0.00496	CcSEcCtD
Prazosin—Epistaxis—Paclitaxel—ovarian cancer	0.000398	0.00494	CcSEcCtD
Prazosin—Fatigue—Melphalan—ovarian cancer	0.000395	0.0049	CcSEcCtD
Prazosin—Pain—Melphalan—ovarian cancer	0.000392	0.00486	CcSEcCtD
Prazosin—Angina pectoris—Docetaxel—ovarian cancer	0.000391	0.00485	CcSEcCtD
Prazosin—Tachycardia—Vinorelbine—ovarian cancer	0.000391	0.00484	CcSEcCtD
Prazosin—Hypersensitivity—Chlorambucil—ovarian cancer	0.000387	0.0048	CcSEcCtD
Prazosin—Bradycardia—Paclitaxel—ovarian cancer	0.000386	0.00478	CcSEcCtD
Prazosin—Feeling abnormal—Topotecan—ovarian cancer	0.000386	0.00478	CcSEcCtD
Prazosin—Asthenia—Chlorambucil—ovarian cancer	0.000377	0.00467	CcSEcCtD
Prazosin—Pruritus—Chlorambucil—ovarian cancer	0.000372	0.00461	CcSEcCtD
Prazosin—Urticaria—Topotecan—ovarian cancer	0.000372	0.00461	CcSEcCtD
Prazosin—Body temperature increased—Topotecan—ovarian cancer	0.00037	0.00459	CcSEcCtD
Prazosin—ADRA2A—testis—ovarian cancer	0.000365	0.00723	CbGeAlD
Prazosin—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.000365	0.00452	CcSEcCtD
Prazosin—Urticaria—Melphalan—ovarian cancer	0.000364	0.00451	CcSEcCtD
Prazosin—Diarrhoea—Chlorambucil—ovarian cancer	0.00036	0.00446	CcSEcCtD
Prazosin—Paraesthesia—Vinorelbine—ovarian cancer	0.00036	0.00446	CcSEcCtD
Prazosin—Dyspnoea—Vinorelbine—ovarian cancer	0.000357	0.00442	CcSEcCtD
Prazosin—Tinnitus—Paclitaxel—ovarian cancer	0.000353	0.00438	CcSEcCtD
Prazosin—Flushing—Paclitaxel—ovarian cancer	0.000352	0.00436	CcSEcCtD
Prazosin—Eye pain—Epirubicin—ovarian cancer	0.000347	0.0043	CcSEcCtD
Prazosin—Fatigue—Vinorelbine—ovarian cancer	0.000345	0.00428	CcSEcCtD
Prazosin—Hypersensitivity—Topotecan—ovarian cancer	0.000345	0.00427	CcSEcCtD
Prazosin—Constipation—Vinorelbine—ovarian cancer	0.000342	0.00424	CcSEcCtD
Prazosin—Pain—Vinorelbine—ovarian cancer	0.000342	0.00424	CcSEcCtD
Prazosin—ABCB1—epithelium—ovarian cancer	0.000339	0.00672	CbGeAlD
Prazosin—Hypersensitivity—Melphalan—ovarian cancer	0.000338	0.00418	CcSEcCtD
Prazosin—Epistaxis—Docetaxel—ovarian cancer	0.000338	0.00418	CcSEcCtD
Prazosin—ABCB1—uterine cervix—ovarian cancer	0.000336	0.00666	CbGeAlD
Prazosin—KCNH2—lymph node—ovarian cancer	0.000336	0.00666	CbGeAlD
Prazosin—Asthenia—Topotecan—ovarian cancer	0.000336	0.00416	CcSEcCtD
Prazosin—Alopecia—Paclitaxel—ovarian cancer	0.000335	0.00415	CcSEcCtD
Prazosin—Vomiting—Chlorambucil—ovarian cancer	0.000334	0.00414	CcSEcCtD
Prazosin—Pruritus—Topotecan—ovarian cancer	0.000331	0.0041	CcSEcCtD
Prazosin—Feeling abnormal—Vinorelbine—ovarian cancer	0.00033	0.00409	CcSEcCtD
Prazosin—Asthenia—Melphalan—ovarian cancer	0.000329	0.00407	CcSEcCtD
Prazosin—Pruritus—Melphalan—ovarian cancer	0.000324	0.00402	CcSEcCtD
Prazosin—Tension—Paclitaxel—ovarian cancer	0.000324	0.00401	CcSEcCtD
Prazosin—Eye pain—Doxorubicin—ovarian cancer	0.000321	0.00398	CcSEcCtD
Prazosin—Nervousness—Paclitaxel—ovarian cancer	0.00032	0.00397	CcSEcCtD
Prazosin—ABCB1—decidua—ovarian cancer	0.00032	0.00635	CbGeAlD
Prazosin—Diarrhoea—Topotecan—ovarian cancer	0.00032	0.00397	CcSEcCtD
Prazosin—Urticaria—Vinorelbine—ovarian cancer	0.000318	0.00394	CcSEcCtD
Prazosin—Body temperature increased—Vinorelbine—ovarian cancer	0.000317	0.00392	CcSEcCtD
Prazosin—Diarrhoea—Melphalan—ovarian cancer	0.000314	0.00389	CcSEcCtD
Prazosin—Nausea—Chlorambucil—ovarian cancer	0.000312	0.00387	CcSEcCtD
Prazosin—Vision blurred—Paclitaxel—ovarian cancer	0.000311	0.00385	CcSEcCtD
Prazosin—Dizziness—Topotecan—ovarian cancer	0.00031	0.00384	CcSEcCtD
Prazosin—Ill-defined disorder—Paclitaxel—ovarian cancer	0.000306	0.00379	CcSEcCtD
Prazosin—ABCB1—endometrium—ovarian cancer	0.000304	0.00603	CbGeAlD
Prazosin—ABCG2—lymph node—ovarian cancer	0.000299	0.00592	CbGeAlD
Prazosin—Flushing—Docetaxel—ovarian cancer	0.000298	0.0037	CcSEcCtD
Prazosin—Vomiting—Topotecan—ovarian cancer	0.000298	0.00369	CcSEcCtD
Prazosin—Malaise—Paclitaxel—ovarian cancer	0.000298	0.00369	CcSEcCtD
Prazosin—Vertigo—Paclitaxel—ovarian cancer	0.000296	0.00367	CcSEcCtD
Prazosin—Syncope—Paclitaxel—ovarian cancer	0.000296	0.00367	CcSEcCtD
Prazosin—Rash—Topotecan—ovarian cancer	0.000295	0.00366	CcSEcCtD
Prazosin—Hypersensitivity—Vinorelbine—ovarian cancer	0.000295	0.00366	CcSEcCtD
Prazosin—Dermatitis—Topotecan—ovarian cancer	0.000295	0.00365	CcSEcCtD
Prazosin—Headache—Topotecan—ovarian cancer	0.000293	0.00363	CcSEcCtD
Prazosin—Palpitations—Paclitaxel—ovarian cancer	0.000292	0.00361	CcSEcCtD
Prazosin—Vomiting—Melphalan—ovarian cancer	0.000291	0.00361	CcSEcCtD
Prazosin—Loss of consciousness—Paclitaxel—ovarian cancer	0.00029	0.00359	CcSEcCtD
Prazosin—Rash—Melphalan—ovarian cancer	0.000289	0.00358	CcSEcCtD
Prazosin—Dermatitis—Melphalan—ovarian cancer	0.000289	0.00358	CcSEcCtD
Prazosin—Asthenia—Vinorelbine—ovarian cancer	0.000287	0.00356	CcSEcCtD
Prazosin—Orthostatic hypotension—Epirubicin—ovarian cancer	0.000286	0.00355	CcSEcCtD
Prazosin—Alopecia—Docetaxel—ovarian cancer	0.000284	0.00352	CcSEcCtD
Prazosin—CYP1A1—lymph node—ovarian cancer	0.000284	0.00562	CbGeAlD
Prazosin—Pruritus—Vinorelbine—ovarian cancer	0.000283	0.00351	CcSEcCtD
Prazosin—ABCB1—gonad—ovarian cancer	0.000282	0.00559	CbGeAlD
Prazosin—Arthralgia—Paclitaxel—ovarian cancer	0.000281	0.00348	CcSEcCtD
Prazosin—ABCB1—uterus—ovarian cancer	0.00028	0.00555	CbGeAlD
Prazosin—Nausea—Topotecan—ovarian cancer	0.000278	0.00345	CcSEcCtD
Prazosin—Discomfort—Paclitaxel—ovarian cancer	0.000278	0.00344	CcSEcCtD
Prazosin—Dry mouth—Paclitaxel—ovarian cancer	0.000275	0.0034	CcSEcCtD
Prazosin—Diarrhoea—Vinorelbine—ovarian cancer	0.000274	0.00339	CcSEcCtD
Prazosin—Nausea—Melphalan—ovarian cancer	0.000272	0.00337	CcSEcCtD
Prazosin—Oedema—Paclitaxel—ovarian cancer	0.000269	0.00334	CcSEcCtD
Prazosin—Pancreatitis—Epirubicin—ovarian cancer	0.000265	0.00329	CcSEcCtD
Prazosin—Shock—Paclitaxel—ovarian cancer	0.000265	0.00328	CcSEcCtD
Prazosin—Dizziness—Vinorelbine—ovarian cancer	0.000265	0.00328	CcSEcCtD
Prazosin—Orthostatic hypotension—Doxorubicin—ovarian cancer	0.000265	0.00328	CcSEcCtD
Prazosin—ADRA2A—lymph node—ovarian cancer	0.000265	0.00524	CbGeAlD
Prazosin—Angina pectoris—Epirubicin—ovarian cancer	0.000264	0.00327	CcSEcCtD
Prazosin—Tachycardia—Paclitaxel—ovarian cancer	0.000263	0.00326	CcSEcCtD
Prazosin—Hyperhidrosis—Paclitaxel—ovarian cancer	0.00026	0.00323	CcSEcCtD
Prazosin—Vomiting—Vinorelbine—ovarian cancer	0.000255	0.00315	CcSEcCtD
Prazosin—Rash—Vinorelbine—ovarian cancer	0.000252	0.00313	CcSEcCtD
Prazosin—Dermatitis—Vinorelbine—ovarian cancer	0.000252	0.00313	CcSEcCtD
Prazosin—ABCB1—female reproductive system—ovarian cancer	0.000252	0.00499	CbGeAlD
Prazosin—Headache—Vinorelbine—ovarian cancer	0.000251	0.00311	CcSEcCtD
Prazosin—Syncope—Docetaxel—ovarian cancer	0.000251	0.00311	CcSEcCtD
Prazosin—Pollakiuria—Epirubicin—ovarian cancer	0.00025	0.0031	CcSEcCtD
Prazosin—Palpitations—Docetaxel—ovarian cancer	0.000247	0.00306	CcSEcCtD
Prazosin—Loss of consciousness—Docetaxel—ovarian cancer	0.000246	0.00305	CcSEcCtD
Prazosin—Pancreatitis—Doxorubicin—ovarian cancer	0.000246	0.00304	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000245	0.00304	CcSEcCtD
Prazosin—Angina pectoris—Doxorubicin—ovarian cancer	0.000244	0.00302	CcSEcCtD
Prazosin—Insomnia—Paclitaxel—ovarian cancer	0.000244	0.00302	CcSEcCtD
Prazosin—Paraesthesia—Paclitaxel—ovarian cancer	0.000242	0.003	CcSEcCtD
Prazosin—Drowsiness—Epirubicin—ovarian cancer	0.000241	0.00299	CcSEcCtD
Prazosin—Dyspnoea—Paclitaxel—ovarian cancer	0.00024	0.00298	CcSEcCtD
Prazosin—Somnolence—Paclitaxel—ovarian cancer	0.000239	0.00297	CcSEcCtD
Prazosin—Arthralgia—Docetaxel—ovarian cancer	0.000238	0.00295	CcSEcCtD
Prazosin—ABCB1—bone marrow—ovarian cancer	0.000238	0.00471	CbGeAlD
Prazosin—Nausea—Vinorelbine—ovarian cancer	0.000238	0.00295	CcSEcCtD
Prazosin—Dry mouth—Docetaxel—ovarian cancer	0.000233	0.00289	CcSEcCtD
Prazosin—Fatigue—Paclitaxel—ovarian cancer	0.000232	0.00288	CcSEcCtD
Prazosin—Pollakiuria—Doxorubicin—ovarian cancer	0.000231	0.00287	CcSEcCtD
Prazosin—Pain—Paclitaxel—ovarian cancer	0.00023	0.00285	CcSEcCtD
Prazosin—Constipation—Paclitaxel—ovarian cancer	0.00023	0.00285	CcSEcCtD
Prazosin—ABCB1—female gonad—ovarian cancer	0.000229	0.00454	CbGeAlD
Prazosin—Oedema—Docetaxel—ovarian cancer	0.000228	0.00283	CcSEcCtD
Prazosin—ABCB1—vagina—ovarian cancer	0.000228	0.00452	CbGeAlD
Prazosin—Epistaxis—Epirubicin—ovarian cancer	0.000228	0.00282	CcSEcCtD
Prazosin—Shock—Docetaxel—ovarian cancer	0.000225	0.00278	CcSEcCtD
Prazosin—Drowsiness—Doxorubicin—ovarian cancer	0.000223	0.00277	CcSEcCtD
Prazosin—Tachycardia—Docetaxel—ovarian cancer	0.000223	0.00276	CcSEcCtD
Prazosin—Feeling abnormal—Paclitaxel—ovarian cancer	0.000222	0.00275	CcSEcCtD
Prazosin—Bradycardia—Epirubicin—ovarian cancer	0.000221	0.00273	CcSEcCtD
Prazosin—Urticaria—Paclitaxel—ovarian cancer	0.000214	0.00265	CcSEcCtD
Prazosin—Body temperature increased—Paclitaxel—ovarian cancer	0.000213	0.00264	CcSEcCtD
Prazosin—Epistaxis—Doxorubicin—ovarian cancer	0.000211	0.00261	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000208	0.00258	CcSEcCtD
Prazosin—Insomnia—Docetaxel—ovarian cancer	0.000206	0.00256	CcSEcCtD
Prazosin—Paraesthesia—Docetaxel—ovarian cancer	0.000205	0.00254	CcSEcCtD
Prazosin—Bradycardia—Doxorubicin—ovarian cancer	0.000204	0.00253	CcSEcCtD
Prazosin—Dyspnoea—Docetaxel—ovarian cancer	0.000204	0.00252	CcSEcCtD
Prazosin—ABCB1—testis—ovarian cancer	0.000203	0.00403	CbGeAlD
Prazosin—Somnolence—Docetaxel—ovarian cancer	0.000203	0.00251	CcSEcCtD
Prazosin—Tinnitus—Epirubicin—ovarian cancer	0.000202	0.0025	CcSEcCtD
Prazosin—Flushing—Epirubicin—ovarian cancer	0.000201	0.00249	CcSEcCtD
Prazosin—Hypersensitivity—Paclitaxel—ovarian cancer	0.000198	0.00246	CcSEcCtD
Prazosin—Fatigue—Docetaxel—ovarian cancer	0.000197	0.00244	CcSEcCtD
Prazosin—Pain—Docetaxel—ovarian cancer	0.000195	0.00242	CcSEcCtD
Prazosin—Constipation—Docetaxel—ovarian cancer	0.000195	0.00242	CcSEcCtD
Prazosin—Asthenia—Paclitaxel—ovarian cancer	0.000193	0.00239	CcSEcCtD
Prazosin—Alopecia—Epirubicin—ovarian cancer	0.000192	0.00237	CcSEcCtD
Prazosin—Pruritus—Paclitaxel—ovarian cancer	0.000191	0.00236	CcSEcCtD
Prazosin—Feeling abnormal—Docetaxel—ovarian cancer	0.000188	0.00233	CcSEcCtD
Prazosin—Tinnitus—Doxorubicin—ovarian cancer	0.000187	0.00232	CcSEcCtD
Prazosin—Flushing—Doxorubicin—ovarian cancer	0.000186	0.00231	CcSEcCtD
Prazosin—Tension—Epirubicin—ovarian cancer	0.000185	0.00229	CcSEcCtD
Prazosin—Diarrhoea—Paclitaxel—ovarian cancer	0.000184	0.00228	CcSEcCtD
Prazosin—Nervousness—Epirubicin—ovarian cancer	0.000183	0.00227	CcSEcCtD
Prazosin—Body temperature increased—Docetaxel—ovarian cancer	0.00018	0.00224	CcSEcCtD
Prazosin—Dizziness—Paclitaxel—ovarian cancer	0.000178	0.00221	CcSEcCtD
Prazosin—Vision blurred—Epirubicin—ovarian cancer	0.000178	0.0022	CcSEcCtD
Prazosin—Alopecia—Doxorubicin—ovarian cancer	0.000177	0.0022	CcSEcCtD
Prazosin—Ill-defined disorder—Epirubicin—ovarian cancer	0.000175	0.00217	CcSEcCtD
Prazosin—Tension—Doxorubicin—ovarian cancer	0.000171	0.00212	CcSEcCtD
Prazosin—Vomiting—Paclitaxel—ovarian cancer	0.000171	0.00212	CcSEcCtD
Prazosin—Malaise—Epirubicin—ovarian cancer	0.00017	0.00211	CcSEcCtD
Prazosin—Rash—Paclitaxel—ovarian cancer	0.00017	0.0021	CcSEcCtD
Prazosin—Dermatitis—Paclitaxel—ovarian cancer	0.00017	0.0021	CcSEcCtD
Prazosin—Nervousness—Doxorubicin—ovarian cancer	0.00017	0.0021	CcSEcCtD
Prazosin—Vertigo—Epirubicin—ovarian cancer	0.000169	0.0021	CcSEcCtD
Prazosin—Syncope—Epirubicin—ovarian cancer	0.000169	0.0021	CcSEcCtD
Prazosin—Headache—Paclitaxel—ovarian cancer	0.000169	0.00209	CcSEcCtD
Prazosin—Hypersensitivity—Docetaxel—ovarian cancer	0.000168	0.00208	CcSEcCtD
Prazosin—Palpitations—Epirubicin—ovarian cancer	0.000167	0.00207	CcSEcCtD
Prazosin—Loss of consciousness—Epirubicin—ovarian cancer	0.000166	0.00205	CcSEcCtD
Prazosin—Vision blurred—Doxorubicin—ovarian cancer	0.000165	0.00204	CcSEcCtD
Prazosin—Asthenia—Docetaxel—ovarian cancer	0.000164	0.00203	CcSEcCtD
Prazosin—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000162	0.00201	CcSEcCtD
Prazosin—Pruritus—Docetaxel—ovarian cancer	0.000161	0.002	CcSEcCtD
Prazosin—Arthralgia—Epirubicin—ovarian cancer	0.000161	0.00199	CcSEcCtD
Prazosin—Nausea—Paclitaxel—ovarian cancer	0.00016	0.00198	CcSEcCtD
Prazosin—Discomfort—Epirubicin—ovarian cancer	0.000159	0.00197	CcSEcCtD
Prazosin—Malaise—Doxorubicin—ovarian cancer	0.000157	0.00195	CcSEcCtD
Prazosin—Dry mouth—Epirubicin—ovarian cancer	0.000157	0.00195	CcSEcCtD
Prazosin—Vertigo—Doxorubicin—ovarian cancer	0.000157	0.00194	CcSEcCtD
Prazosin—Syncope—Doxorubicin—ovarian cancer	0.000157	0.00194	CcSEcCtD
Prazosin—Diarrhoea—Docetaxel—ovarian cancer	0.000156	0.00194	CcSEcCtD
Prazosin—Palpitations—Doxorubicin—ovarian cancer	0.000154	0.00191	CcSEcCtD
Prazosin—Oedema—Epirubicin—ovarian cancer	0.000154	0.00191	CcSEcCtD
Prazosin—Loss of consciousness—Doxorubicin—ovarian cancer	0.000153	0.0019	CcSEcCtD
Prazosin—Shock—Epirubicin—ovarian cancer	0.000151	0.00188	CcSEcCtD
Prazosin—Dizziness—Docetaxel—ovarian cancer	0.000151	0.00187	CcSEcCtD
Prazosin—Tachycardia—Epirubicin—ovarian cancer	0.00015	0.00186	CcSEcCtD
Prazosin—Hyperhidrosis—Epirubicin—ovarian cancer	0.000149	0.00184	CcSEcCtD
Prazosin—Arthralgia—Doxorubicin—ovarian cancer	0.000149	0.00184	CcSEcCtD
Prazosin—ABCB1—lymph node—ovarian cancer	0.000147	0.00292	CbGeAlD
Prazosin—Discomfort—Doxorubicin—ovarian cancer	0.000147	0.00182	CcSEcCtD
Prazosin—Dry mouth—Doxorubicin—ovarian cancer	0.000145	0.0018	CcSEcCtD
Prazosin—Vomiting—Docetaxel—ovarian cancer	0.000145	0.0018	CcSEcCtD
Prazosin—Rash—Docetaxel—ovarian cancer	0.000144	0.00178	CcSEcCtD
Prazosin—Dermatitis—Docetaxel—ovarian cancer	0.000144	0.00178	CcSEcCtD
Prazosin—Headache—Docetaxel—ovarian cancer	0.000143	0.00177	CcSEcCtD
Prazosin—Oedema—Doxorubicin—ovarian cancer	0.000142	0.00177	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.00014	0.00174	CcSEcCtD
Prazosin—Shock—Doxorubicin—ovarian cancer	0.00014	0.00174	CcSEcCtD
Prazosin—Insomnia—Epirubicin—ovarian cancer	0.000139	0.00173	CcSEcCtD
Prazosin—Tachycardia—Doxorubicin—ovarian cancer	0.000139	0.00172	CcSEcCtD
Prazosin—Paraesthesia—Epirubicin—ovarian cancer	0.000138	0.00171	CcSEcCtD
Prazosin—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000138	0.00171	CcSEcCtD
Prazosin—Dyspnoea—Epirubicin—ovarian cancer	0.000137	0.0017	CcSEcCtD
Prazosin—Somnolence—Epirubicin—ovarian cancer	0.000137	0.0017	CcSEcCtD
Prazosin—Nausea—Docetaxel—ovarian cancer	0.000136	0.00168	CcSEcCtD
Prazosin—Fatigue—Epirubicin—ovarian cancer	0.000133	0.00164	CcSEcCtD
Prazosin—Pain—Epirubicin—ovarian cancer	0.000132	0.00163	CcSEcCtD
Prazosin—Constipation—Epirubicin—ovarian cancer	0.000132	0.00163	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.00013	0.00161	CcSEcCtD
Prazosin—Insomnia—Doxorubicin—ovarian cancer	0.000129	0.0016	CcSEcCtD
Prazosin—Paraesthesia—Doxorubicin—ovarian cancer	0.000128	0.00159	CcSEcCtD
Prazosin—Dyspnoea—Doxorubicin—ovarian cancer	0.000127	0.00157	CcSEcCtD
Prazosin—Feeling abnormal—Epirubicin—ovarian cancer	0.000127	0.00157	CcSEcCtD
Prazosin—Somnolence—Doxorubicin—ovarian cancer	0.000127	0.00157	CcSEcCtD
Prazosin—Fatigue—Doxorubicin—ovarian cancer	0.000123	0.00152	CcSEcCtD
Prazosin—Urticaria—Epirubicin—ovarian cancer	0.000122	0.00152	CcSEcCtD
Prazosin—Pain—Doxorubicin—ovarian cancer	0.000122	0.00151	CcSEcCtD
Prazosin—Constipation—Doxorubicin—ovarian cancer	0.000122	0.00151	CcSEcCtD
Prazosin—Body temperature increased—Epirubicin—ovarian cancer	0.000122	0.00151	CcSEcCtD
Prazosin—Feeling abnormal—Doxorubicin—ovarian cancer	0.000117	0.00145	CcSEcCtD
Prazosin—Hypersensitivity—Epirubicin—ovarian cancer	0.000113	0.00141	CcSEcCtD
Prazosin—Urticaria—Doxorubicin—ovarian cancer	0.000113	0.0014	CcSEcCtD
Prazosin—Body temperature increased—Doxorubicin—ovarian cancer	0.000113	0.0014	CcSEcCtD
Prazosin—Asthenia—Epirubicin—ovarian cancer	0.00011	0.00137	CcSEcCtD
Prazosin—Pruritus—Epirubicin—ovarian cancer	0.000109	0.00135	CcSEcCtD
Prazosin—Diarrhoea—Epirubicin—ovarian cancer	0.000105	0.00131	CcSEcCtD
Prazosin—Hypersensitivity—Doxorubicin—ovarian cancer	0.000105	0.0013	CcSEcCtD
Prazosin—Asthenia—Doxorubicin—ovarian cancer	0.000102	0.00127	CcSEcCtD
Prazosin—Dizziness—Epirubicin—ovarian cancer	0.000102	0.00126	CcSEcCtD
Prazosin—Pruritus—Doxorubicin—ovarian cancer	0.000101	0.00125	CcSEcCtD
Prazosin—Vomiting—Epirubicin—ovarian cancer	9.79e-05	0.00121	CcSEcCtD
Prazosin—Diarrhoea—Doxorubicin—ovarian cancer	9.75e-05	0.00121	CcSEcCtD
Prazosin—Rash—Epirubicin—ovarian cancer	9.71e-05	0.0012	CcSEcCtD
Prazosin—Dermatitis—Epirubicin—ovarian cancer	9.7e-05	0.0012	CcSEcCtD
Prazosin—Headache—Epirubicin—ovarian cancer	9.65e-05	0.0012	CcSEcCtD
Prazosin—Dizziness—Doxorubicin—ovarian cancer	9.42e-05	0.00117	CcSEcCtD
Prazosin—Nausea—Epirubicin—ovarian cancer	9.15e-05	0.00113	CcSEcCtD
Prazosin—Vomiting—Doxorubicin—ovarian cancer	9.06e-05	0.00112	CcSEcCtD
Prazosin—Rash—Doxorubicin—ovarian cancer	8.98e-05	0.00111	CcSEcCtD
Prazosin—Dermatitis—Doxorubicin—ovarian cancer	8.97e-05	0.00111	CcSEcCtD
Prazosin—Headache—Doxorubicin—ovarian cancer	8.92e-05	0.00111	CcSEcCtD
Prazosin—Nausea—Doxorubicin—ovarian cancer	8.46e-05	0.00105	CcSEcCtD
Prazosin—HTR1D—Signaling Pathways—PTEN—ovarian cancer	6.15e-06	0.000126	CbGpPWpGaD
Prazosin—SLC22A3—Metabolism—PIK3CA—ovarian cancer	6.14e-06	0.000125	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—TYMS—ovarian cancer	6.13e-06	0.000125	CbGpPWpGaD
Prazosin—ADRA2A—Hemostasis—AKT1—ovarian cancer	6.13e-06	0.000125	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IL6ST—ovarian cancer	6.1e-06	0.000125	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MTOR—ovarian cancer	6.09e-06	0.000124	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—PIK3CB—ovarian cancer	6.09e-06	0.000124	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PIK3CD—ovarian cancer	6.09e-06	0.000124	CbGpPWpGaD
Prazosin—HTR1A—GPCR downstream signaling—PIK3CA—ovarian cancer	6.03e-06	0.000123	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—MAPK1—ovarian cancer	6.01e-06	0.000123	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—EGFR—ovarian cancer	6.01e-06	0.000123	CbGpPWpGaD
Prazosin—HTR1D—Signaling by GPCR—AKT1—ovarian cancer	6e-06	0.000123	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CAV1—ovarian cancer	5.98e-06	0.000122	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—KRAS—ovarian cancer	5.96e-06	0.000122	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.91e-06	0.000121	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PIK3CB—ovarian cancer	5.89e-06	0.00012	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—APC—ovarian cancer	5.86e-06	0.00012	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PIK3CG—ovarian cancer	5.86e-06	0.00012	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—NRAS—ovarian cancer	5.86e-06	0.00012	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CXCL8—ovarian cancer	5.85e-06	0.00012	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—HRAS—ovarian cancer	5.81e-06	0.000119	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PIK3CD—ovarian cancer	5.8e-06	0.000119	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—ESR1—ovarian cancer	5.76e-06	0.000118	CbGpPWpGaD
Prazosin—ADRA1B—GPCR downstream signaling—PIK3CA—ovarian cancer	5.74e-06	0.000117	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PIK3CD—ovarian cancer	5.72e-06	0.000117	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CDKN1B—ovarian cancer	5.72e-06	0.000117	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—KRAS—ovarian cancer	5.68e-06	0.000116	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—PIK3CA—ovarian cancer	5.67e-06	0.000116	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IL6ST—ovarian cancer	5.67e-06	0.000116	CbGpPWpGaD
Prazosin—ADRA1D—GPCR downstream signaling—AKT1—ovarian cancer	5.65e-06	0.000116	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PIK3CG—ovarian cancer	5.64e-06	0.000115	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—MAPK3—ovarian cancer	5.61e-06	0.000115	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CASP3—ovarian cancer	5.6e-06	0.000114	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—IL2—ovarian cancer	5.59e-06	0.000114	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—ERBB2—ovarian cancer	5.57e-06	0.000114	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—IL6—ovarian cancer	5.57e-06	0.000114	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—VEGFA—ovarian cancer	5.55e-06	0.000114	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—PTEN—ovarian cancer	5.51e-06	0.000113	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—STAT3—ovarian cancer	5.5e-06	0.000112	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MTOR—ovarian cancer	5.5e-06	0.000112	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—PIK3CB—ovarian cancer	5.5e-06	0.000112	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—NRAS—ovarian cancer	5.49e-06	0.000112	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—PIK3CA—ovarian cancer	5.48e-06	0.000112	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—PTEN—ovarian cancer	5.46e-06	0.000112	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CCND1—ovarian cancer	5.45e-06	0.000111	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—APC—ovarian cancer	5.44e-06	0.000111	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PIK3CG—ovarian cancer	5.44e-06	0.000111	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—NRAS—ovarian cancer	5.44e-06	0.000111	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CTNNB1—ovarian cancer	5.4e-06	0.00011	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—ERBB2—ovarian cancer	5.38e-06	0.00011	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—MAPK1—ovarian cancer	5.34e-06	0.000109	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—EGFR—ovarian cancer	5.34e-06	0.000109	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MTOR—ovarian cancer	5.31e-06	0.000108	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PIK3CB—ovarian cancer	5.31e-06	0.000108	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MMP9—ovarian cancer	5.29e-06	0.000108	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CXCL8—ovarian cancer	5.28e-06	0.000108	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—PTEN—ovarian cancer	5.26e-06	0.000108	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—MAPK3—ovarian cancer	5.25e-06	0.000107	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—HRAS—ovarian cancer	5.25e-06	0.000107	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—PIK3CA—ovarian cancer	5.22e-06	0.000107	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—MAPK3—ovarian cancer	5.21e-06	0.000107	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CDKN1B—ovarian cancer	5.16e-06	0.000105	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PIK3CD—ovarian cancer	5.15e-06	0.000105	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—AKT1—ovarian cancer	5.13e-06	0.000105	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—ERBB2—ovarian cancer	5.12e-06	0.000105	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—MYC—ovarian cancer	5.11e-06	0.000104	CbGpPWpGaD
Prazosin—ADRA2B—GPCR downstream signaling—AKT1—ovarian cancer	5.1e-06	0.000104	CbGpPWpGaD
Prazosin—ADRA1A—GPCR downstream signaling—PIK3CA—ovarian cancer	5.1e-06	0.000104	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CXCL8—ovarian cancer	5.1e-06	0.000104	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PTEN—ovarian cancer	5.09e-06	0.000104	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—HRAS—ovarian cancer	5.07e-06	0.000104	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CASP3—ovarian cancer	5.06e-06	0.000103	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MTOR—ovarian cancer	5.06e-06	0.000103	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PIK3CB—ovarian cancer	5.06e-06	0.000103	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—IL2—ovarian cancer	5.05e-06	0.000103	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—KRAS—ovarian cancer	5.04e-06	0.000103	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—IL6—ovarian cancer	5.02e-06	0.000103	CbGpPWpGaD
Prazosin—SLC22A3—Metabolism—AKT1—ovarian cancer	5.01e-06	0.000102	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—MAPK1—ovarian cancer	5e-06	0.000102	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—EGFR—ovarian cancer	5e-06	0.000102	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PIK3CB—ovarian cancer	4.99e-06	0.000102	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CDKN1B—ovarian cancer	4.98e-06	0.000102	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—MAPK1—ovarian cancer	4.96e-06	0.000101	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—EGFR—ovarian cancer	4.96e-06	0.000101	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PIK3CD—ovarian cancer	4.96e-06	0.000101	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—CAV1—ovarian cancer	4.94e-06	0.000101	CbGpPWpGaD
Prazosin—HTR1A—GPCR downstream signaling—AKT1—ovarian cancer	4.93e-06	0.000101	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CCND1—ovarian cancer	4.92e-06	0.000101	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CASP3—ovarian cancer	4.88e-06	9.98e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CTNNB1—ovarian cancer	4.87e-06	9.96e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—IL2—ovarian cancer	4.87e-06	9.96e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CXCL8—ovarian cancer	4.86e-06	9.93e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—IL6—ovarian cancer	4.85e-06	9.91e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—HRAS—ovarian cancer	4.83e-06	9.86e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PIK3CD—ovarian cancer	4.79e-06	9.78e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MMP9—ovarian cancer	4.78e-06	9.77e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—VEGFA—ovarian cancer	4.75e-06	9.72e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CCND1—ovarian cancer	4.75e-06	9.71e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—PTEN—ovarian cancer	4.75e-06	9.71e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CDKN1B—ovarian cancer	4.74e-06	9.7e-05	CbGpPWpGaD
Prazosin—ADRA2A—GPCR downstream signaling—PIK3CA—ovarian cancer	4.74e-06	9.69e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—KRAS—ovarian cancer	4.72e-06	9.65e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—STAT3—ovarian cancer	4.71e-06	9.62e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CTNNB1—ovarian cancer	4.71e-06	9.62e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—NRAS—ovarian cancer	4.7e-06	9.6e-05	CbGpPWpGaD
Prazosin—ADRA1B—GPCR downstream signaling—AKT1—ovarian cancer	4.69e-06	9.59e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—KRAS—ovarian cancer	4.69e-06	9.58e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CASP3—ovarian cancer	4.65e-06	9.5e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—IL2—ovarian cancer	4.64e-06	9.49e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—AKT1—ovarian cancer	4.64e-06	9.47e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—PIK3CA—ovarian cancer	4.63e-06	9.47e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—IL6—ovarian cancer	4.62e-06	9.44e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MMP9—ovarian cancer	4.61e-06	9.43e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PTEN—ovarian cancer	4.59e-06	9.37e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—ERBB2—ovarian cancer	4.55e-06	9.3e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CCND1—ovarian cancer	4.53e-06	9.25e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3CG—ovarian cancer	4.5e-06	9.2e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MAPK3—ovarian cancer	4.5e-06	9.19e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PIK3CB—ovarian cancer	4.49e-06	9.18e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MTOR—ovarian cancer	4.49e-06	9.18e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CTNNB1—ovarian cancer	4.48e-06	9.16e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—AKT1—ovarian cancer	4.47e-06	9.15e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MMP9—ovarian cancer	4.39e-06	8.98e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MYC—ovarian cancer	4.37e-06	8.94e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PTEN—ovarian cancer	4.37e-06	8.93e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—PIK3CA—ovarian cancer	4.34e-06	8.87e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PIK3CB—ovarian cancer	4.32e-06	8.83e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CXCL8—ovarian cancer	4.31e-06	8.82e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PTEN—ovarian cancer	4.31e-06	8.81e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—PIK3CA—ovarian cancer	4.31e-06	8.8e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—VEGFA—ovarian cancer	4.29e-06	8.77e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—HRAS—ovarian cancer	4.29e-06	8.76e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MAPK1—ovarian cancer	4.28e-06	8.74e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—EGFR—ovarian cancer	4.28e-06	8.74e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—AKT1—ovarian cancer	4.26e-06	8.71e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—STAT3—ovarian cancer	4.25e-06	8.69e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—NRAS—ovarian cancer	4.24e-06	8.66e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—ERBB2—ovarian cancer	4.23e-06	8.64e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CDKN1B—ovarian cancer	4.21e-06	8.61e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—TP53—ovarian cancer	4.2e-06	8.58e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MTOR—ovarian cancer	4.17e-06	8.53e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PIK3CB—ovarian cancer	4.17e-06	8.53e-05	CbGpPWpGaD
Prazosin—ADRA1A—GPCR downstream signaling—AKT1—ovarian cancer	4.17e-06	8.52e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—VEGFA—ovarian cancer	4.14e-06	8.47e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CASP3—ovarian cancer	4.13e-06	8.44e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IL2—ovarian cancer	4.12e-06	8.43e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—IL6—ovarian cancer	4.1e-06	8.39e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—STAT3—ovarian cancer	4.1e-06	8.38e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—NRAS—ovarian cancer	4.09e-06	8.36e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MAPK3—ovarian cancer	4.06e-06	8.3e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—KRAS—ovarian cancer	4.04e-06	8.26e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CCND1—ovarian cancer	4.02e-06	8.22e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—HRAS—ovarian cancer	4.01e-06	8.2e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	4.01e-06	8.19e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	3.98e-06	8.14e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CTNNB1—ovarian cancer	3.98e-06	8.14e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3CD—ovarian cancer	3.96e-06	8.09e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MYC—ovarian cancer	3.95e-06	8.07e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—VEGFA—ovarian cancer	3.95e-06	8.06e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MAPK3—ovarian cancer	3.92e-06	8.01e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	3.92e-06	8e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—STAT3—ovarian cancer	3.91e-06	7.98e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MMP9—ovarian cancer	3.9e-06	7.98e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—NRAS—ovarian cancer	3.9e-06	7.96e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—PIK3CA—ovarian cancer	3.89e-06	7.95e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PTEN—ovarian cancer	3.88e-06	7.93e-05	CbGpPWpGaD
Prazosin—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	3.87e-06	7.92e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MAPK1—ovarian cancer	3.86e-06	7.9e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—EGFR—ovarian cancer	3.86e-06	7.89e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—PIK3CA—ovarian cancer	3.85e-06	7.87e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—IL6—ovarian cancer	3.84e-06	7.85e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	3.84e-06	7.84e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IL2—ovarian cancer	3.83e-06	7.83e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	3.81e-06	7.79e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MYC—ovarian cancer	3.81e-06	7.79e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—AKT1—ovarian cancer	3.79e-06	7.74e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	3.73e-06	7.63e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PTEN—ovarian cancer	3.73e-06	7.63e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MAPK3—ovarian cancer	3.73e-06	7.63e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MAPK1—ovarian cancer	3.73e-06	7.62e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—EGFR—ovarian cancer	3.73e-06	7.62e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—PIK3CA—ovarian cancer	3.71e-06	7.59e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	3.7e-06	7.56e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—KRAS—ovarian cancer	3.65e-06	7.46e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MYC—ovarian cancer	3.63e-06	7.42e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	3.63e-06	7.41e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	3.61e-06	7.37e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—TP53—ovarian cancer	3.59e-06	7.34e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PIK3CA—ovarian cancer	3.59e-06	7.33e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MAPK1—ovarian cancer	3.55e-06	7.26e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—EGFR—ovarian cancer	3.55e-06	7.26e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—AKT1—ovarian cancer	3.54e-06	7.24e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—KRAS—ovarian cancer	3.52e-06	7.2e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	3.52e-06	7.19e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—VEGFA—ovarian cancer	3.5e-06	7.16e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—STAT3—ovarian cancer	3.47e-06	7.09e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—NRAS—ovarian cancer	3.46e-06	7.07e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3CB—ovarian cancer	3.45e-06	7.05e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—HRAS—ovarian cancer	3.44e-06	7.02e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—KRAS—ovarian cancer	3.35e-06	6.86e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—PIK3CA—ovarian cancer	3.35e-06	6.85e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MAPK3—ovarian cancer	3.32e-06	6.78e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—IL6—ovarian cancer	3.29e-06	6.72e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	3.26e-06	6.66e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—TP53—ovarian cancer	3.24e-06	6.63e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PIK3CA—ovarian cancer	3.24e-06	6.61e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MYC—ovarian cancer	3.22e-06	6.59e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	3.22e-06	6.59e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	3.22e-06	6.57e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—AKT1—ovarian cancer	3.18e-06	6.5e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MAPK1—ovarian cancer	3.15e-06	6.45e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—EGFR—ovarian cancer	3.15e-06	6.45e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—AKT1—ovarian cancer	3.15e-06	6.43e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—TP53—ovarian cancer	3.13e-06	6.4e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—HRAS—ovarian cancer	3.1e-06	6.34e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PIK3CA—ovarian cancer	3.08e-06	6.3e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	3.08e-06	6.3e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PIK3CA—ovarian cancer	3.04e-06	6.22e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—AKT1—ovarian cancer	3.03e-06	6.2e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MYC—ovarian cancer	3e-06	6.12e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—HRAS—ovarian cancer	2.99e-06	6.12e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PTEN—ovarian cancer	2.98e-06	6.09e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—TP53—ovarian cancer	2.98e-06	6.09e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—KRAS—ovarian cancer	2.98e-06	6.09e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—IL6—ovarian cancer	2.97e-06	6.07e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—AKT1—ovarian cancer	2.93e-06	5.99e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	2.93e-06	5.99e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	2.93e-06	5.99e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—IL6—ovarian cancer	2.87e-06	5.86e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—HRAS—ovarian cancer	2.85e-06	5.83e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	2.77e-06	5.66e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—AKT1—ovarian cancer	2.74e-06	5.6e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PIK3CA—ovarian cancer	2.74e-06	5.59e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—IL6—ovarian cancer	2.73e-06	5.58e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—TP53—ovarian cancer	2.65e-06	5.41e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—AKT1—ovarian cancer	2.64e-06	5.4e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PIK3CA—ovarian cancer	2.63e-06	5.38e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	2.54e-06	5.2e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—HRAS—ovarian cancer	2.53e-06	5.18e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—AKT1—ovarian cancer	2.52e-06	5.15e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—AKT1—ovarian cancer	2.48e-06	5.08e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—TP53—ovarian cancer	2.46e-06	5.03e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IL6—ovarian cancer	2.42e-06	4.95e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	2.35e-06	4.81e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IL6—ovarian cancer	2.25e-06	4.6e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—AKT1—ovarian cancer	2.24e-06	4.57e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—AKT1—ovarian cancer	2.15e-06	4.4e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PIK3CA—ovarian cancer	2.1e-06	4.3e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	2.08e-06	4.25e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—AKT1—ovarian cancer	1.72e-06	3.51e-05	CbGpPWpGaD
